Efficacy of an Asian Culture-tailored Lung Health (ACT) Intervention on Lung Cancer Screening and Smoking Cessation in Asian Americans
Summary
This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
Detailed description
This two-arm stratified randomized clinical trial is to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer. Participants will be randomized into one of two groups: Group A: ACT Lung Health Intervention versus Group B: Standard Care. Randomization means a participant is placed into a study group by chance. The research study procedures include screening for eligibility, questionnaires, and saliva tests. It is expected participation in this study will last about 6 months. About 50 participants are expected to take part in this research study. The National Cancer Institute is providing funding for this trial.
Arms & interventions
- BehavioralACT Lung Health Intervention
An Asian culture-tailored lung health intervention, which includes individual counseling sessions, family coaching, provision of nicotine replacement therapy (NRT) in the form of patches, lozenges, or chewing gum, and educational materials about low-dose computed tomography (LDCT) for lung cancer screening. The eight weekly, counseling sessions with study staff will be conducted via phone call or the Zoom web-conferencing platform.
Outcome measures
Primary
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group A)
The proportion of participants who have not smoked cigarettes (not even a puff) in the past 7 days at the 6-month follow-up, verified biochemically using salivary cotinine testing. Participants reporting abstinence and not using nicotine replacement therapy (NRT) will perform a salivary cotinine test observed via video call. Cotinine levels ≤3 ng/mL will confirm abstinence.
Time frame: 6 months post-baseline assessment
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group B)
The proportion of participants who have not smoked cigarettes (not even a puff) in the past 7 days at the 6-month follow-up, verified biochemically using salivary cotinine testing. Participants reporting abstinence and not using nicotine replacement therapy (NRT) will perform a salivary cotinine test observed via video call. Cotinine levels ≤3 ng/mL will confirm abstinence.
Time frame: 6 months post-baseline assessment
Secondary
Change in Number of Cigarettes Smoked per Day from Baseline to 6 Months (Group A)
Time frame: Baseline and 6 months post-baseline assessment
Change in Number of Cigarettes Smoked per Day from Baseline to 6 Months (Group B)
Time frame: Baseline and 6 months post-baseline assessment
Self-Reported 7-Day Point Prevalence Smoking Abstinence at 3 Months (Group A)
Time frame: 3 months post-baseline assessment
Self-Reported 7-Day Point Prevalence Smoking Abstinence at 3 Months (Group B)
Time frame: 3 months post-baseline assessment
Self-Reported 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group A)
Time frame: 6 months post-baseline assessment
Self-Reported 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group B)
Time frame: 6 months post-baseline assessment
Completion of Lung Cancer Screening with Low-Dose Computed Tomography (LDCT) at 6 Months (Group A)
Time frame: Within 6 months post-baseline assessment
Completion of Lung Cancer Screening with Low-Dose Computed Tomography (LDCT) at 6 Months (Arm B)
Time frame: Within 6 months post-baseline assessment
Eligibility criteria
Study locations (2)
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
University of Massachusetts-Boston
Boston, Massachusetts, 02125